MSB 2.03% $1.45 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-195

  1. 5,491 Posts.
    lightbulb Created with Sketch. 8962
    the FDA make that determination when the re-submission is made by Mesoblast.

    but we can clearly see this is a class 2 CRL... they are asking for another trial.

    Not something we can whip up in a couple of weeks and resubmit. the new trial they want could take a long time to recruit, especially if they want kids in a RCT... it may not even be possible.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.